Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
NASDAQ:VTGN

VistaGen Therapeutics - VTGN Stock Forecast, Price & News

$0.12
-0.01 (-6.04%)
(As of 11/25/2022 08:58 PM ET)
Add
Compare
Today's Range
$0.12
$0.13
50-Day Range
$0.10
$0.18
52-Week Range
$0.08
$2.11
Volume
2.31 million shs
Average Volume
5.67 million shs
Market Capitalization
$25.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
VTGN stock logo

About VistaGen Therapeutics (NASDAQ:VTGN) Stock

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Receive VTGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VistaGen Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VTGN Stock News Headlines

Earnings Outlook For VistaGen Therapeutics
Vistagen to Present at Stifel 2022 Healthcare Conference
VistaGen Therapeutics, Inc. (VTGN)
VistaGen Therapeutics earnings preview: what to expect
See More Headlines
Receive VTGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VistaGen Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VTGN Company Calendar

Last Earnings
11/10/2021
Today
11/28/2022
Next Earnings (Estimated)
2/09/2023
Fiscal Year End
3/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VTGN
Employees
31
Year Founded
N/A

Profitability

Net Income
$-47,760,000.00
Net Margins
-5,614.37%
Pretax Margin
-5,613.99%

Debt

Sales & Book Value

Annual Sales
$1.11 million
Book Value
$0.14 per share

Miscellaneous

Free Float
198,542,000
Market Cap
$25.11 million
Optionable
Not Optionable
Beta
0.48

Key Executives

  • Mr. Shawn K. Singh J.D. (Age 59)
    CEO & Director
    Comp: $912.5k
  • Mr. Jerrold D. Dotson CPA (Age 69)
    CPA, CFO, VP & Sec.
    Comp: $577.5k
  • Mr. Reid G. Adler Esq. (Age 68)
    J.D., Chief Legal Officer
  • Dr. Mark A. Smith M.D. (Age 67)
    Ph.D., Chief Medical Officer
    Comp: $658.75k
  • Ms. Ann Michelle Cunningham M.B.A. (Age 54)
    Chief Commercial Officer & Director
    Comp: $576.44k
  • Mr. Mark Flather
    VP of Investor Relations
  • Mr. Mark Adrian McPartland (Age 56)
    VP of Corp. Devel.
  • Ms. Trisha Fitzmaurice
    VP of HR
  • Dr. Allen Easley Cato III
    M.D., Ph.D., Sr. VP of Devel. Operations
  • Dr. Mark J. Ginski (Age 50)
    Sr. VP and Head of Chemistry, Manufacturing & Controls













VTGN Stock - Frequently Asked Questions

Should I buy or sell VistaGen Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for VistaGen Therapeutics in the last year. There are currently 4 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" VTGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VTGN, but not buy additional shares or sell existing shares.
View VTGN analyst ratings
or view top-rated stocks.

How have VTGN shares performed in 2022?

VistaGen Therapeutics' stock was trading at $1.95 on January 1st, 2022. Since then, VTGN stock has decreased by 93.8% and is now trading at $0.1214.
View the best growth stocks for 2022 here
.

When is VistaGen Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 9th 2023.
View our VTGN earnings forecast
.

How were VistaGen Therapeutics' earnings last quarter?

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.07) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by $0.02. The company earned $0.36 million during the quarter, compared to the consensus estimate of $0.33 million. VistaGen Therapeutics had a negative trailing twelve-month return on equity of 117.05% and a negative net margin of 5,614.37%. During the same quarter in the previous year, the company posted ($0.05) EPS.

What other stocks do shareholders of VistaGen Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VistaGen Therapeutics investors own include Highpower International (HPJ), AK Steel (AKS), Advaxis (ADXS), Matinas BioPharma (MTNB), Rite Aid (RAD), Sorrento Therapeutics (SRNE), Lithium Americas (LAC), ImmunoGen (IMGN), Yamana Gold (AUY) and CRISPR Therapeutics (CRSP).

What is VistaGen Therapeutics' stock symbol?

VistaGen Therapeutics trades on the NASDAQ under the ticker symbol "VTGN."

Who are VistaGen Therapeutics' major shareholders?

VistaGen Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include State Street Corp (2.72%), Vanguard Group Inc. (2.29%), Renaissance Technologies LLC (1.82%), Two Sigma Investments LP (0.41%), Bank of New York Mellon Corp (0.28%) and Two Sigma Advisers LP (0.11%). Insiders that own company stock include H Ralph Snodgrass, Jerrold Duane Dotson, Jerry B Gin, Reid G Adler, Shawn Singh and Venrock Healthcare Capital Par.
View institutional ownership trends
.

How do I buy shares of VistaGen Therapeutics?

Shares of VTGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is VistaGen Therapeutics' stock price today?

One share of VTGN stock can currently be purchased for approximately $0.12.

How much money does VistaGen Therapeutics make?

VistaGen Therapeutics (NASDAQ:VTGN) has a market capitalization of $25.11 million and generates $1.11 million in revenue each year. The company earns $-47,760,000.00 in net income (profit) each year or ($0.31) on an earnings per share basis.

How can I contact VistaGen Therapeutics?

VistaGen Therapeutics' mailing address is 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.vistagen.com. The company can be reached via phone at (650) 577-3600, via email at ir@vistagen.com, or via fax at 888-482-2602.

This page (NASDAQ:VTGN) was last updated on 11/28/2022 by MarketBeat.com Staff